Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

899 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee. Haase D, et al. Among authors: fenaux p. Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11. Leukemia. 2019. PMID: 30635634 Free PMC article.
Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group.
Greenberg P, Anderson J, de Witte T, Estey E, Fenaux P, Gupta P, Hamblin T, Hellstrom-Lindberg E, List A, Mufti G, Neuwirtova R, Ohyashiki K, Oscier D, Sanz G, Sanz M, Willman C. Greenberg P, et al. Among authors: fenaux p. J Clin Oncol. 2000 Oct 1;18(19):3447-52. doi: 10.1200/JCO.2000.18.19.3447. J Clin Oncol. 2000. PMID: 11013289 No abstract available.
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.
Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel MT, Cheze S, Mahé B, Ferrant A, Ravoet C, Escoffre-Barbe M, Adès L, Vey N, Aljassem L, Stamatoullas A, Mannone L, Dombret H, Bourgeois K, Greenberg P, Fenaux P, Dreyfus F; GFM group (Groupe Francophone des Myélodysplasies). Park S, et al. Among authors: fenaux p. Blood. 2008 Jan 15;111(2):574-82. doi: 10.1182/blood-2007-06-096370. Epub 2007 Oct 16. Blood. 2008. PMID: 17940203 Free article. Clinical Trial.
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts.
Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R, Cazzola M, Fenaux P, Germing U, Hellström-Lindberg E, Jinnai I, Manabe A, Matsuda A, Niemeyer CM, Sanz G, Tomonaga M, Vallespi T, Yoshimi A; International Working Group on Morphology of Myelodysplastic Syndrome. Mufti GJ, et al. Among authors: fenaux p. Haematologica. 2008 Nov;93(11):1712-7. doi: 10.3324/haematol.13405. Epub 2008 Oct 6. Haematologica. 2008. PMID: 18838480 Free article.
899 results